

DAFTAR PUSTAKA

- Akram, M., Iqbal, M., Daniyal, M. & Khan, A.U., 2017, Awareness and Current Knowledge of Breast Cancer, *Biological Research*, 50(33), doi: <https://doi.org/10.1186/s40659-017-0140-9>.
- Amandito, R., Viryawan, C., Santoso, F., Gautami, W., Panigoro, S.S., 2013, The Characteristics of Breast Cancer Patients in “Dharmais” Hospital National Cancer Center Jakarta Based on Occupational and Environmental Status, *Indonesian Journal of Cancer*, 7(2), 53-59, doi: <https://doi.org/10.33371/ijoc.v7i2.290>.
- American Cancer Society, 2023, *Breast Cancer*, <https://www.cancer.org/cancer/types/breast-cancer.html>, 9 Oktober 2023.
- American Cancer Society, 2023, *What is Cancer?*, <https://www.cancer.org/cancer/understanding-cancer/what-is-cancer.html>, 8 Oktober 2023.
- Assiri, G.A., Shebl, N.A., Mahmoud, M.A., Aloudah, N., Grant, E., Aljadhey, H. & Sheikh, A., 2018, What is the Epidemiology of Medication Errors, Error-related Adverse Events and Risk Factors for Errors in Adults Managed in Community Care Contexts? A Systematic Review of the International Literature, *BMJ Open*, 8(5), doi: <https://bmjopen.bmj.com/content/8/5/e019101>
- Bain, E., Birhiray, R.E. dan Reeves, D.J., 2014, Drug-drug Interaction Between *Methotrexate* and Levetiracetam Resulting in Delayed *Methotrexate* Elimination, *Annals of Pharmacotherapy*, 48(2), 292-296, doi: <https://doi.org/10.1177/1060028013511951>.
- Badan POM, 2020, *Modul Farmakovigilans untuk Tenaga Profesional Kesehatan*, Jakarta.
- Baxter, K. & Stockley I.H., 2008, *Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management*, Eighth, Pharmaceutical Press, London.
- Bibi, R., Azhar, S., Iqbal, A., Jabeen, H., Kalsoom, U., Iqbal, M.M. & Nazeer, M., 2020, Prevalence of Potential Drug-drug Interactions in Breast Cancer Patients and Determination of Their Risk Factors, *Journal of Oncology Pharmacy Practice*, 0(0), 1-7, doi: <https://doi.org/10.1177/1078155220963212>.
- Benet, L.Z., Bowman, C.M., Koleske, M.L., Rinaldi, C.L. & Sodhi, J.K., 2019, Understanding Drug-Drug Interaction and Pharmacogenomic Changes in Pharmacokinetics for Metabolized Drugs, *Journal of Pharmacokinetics and Pharmacodynamics*, 46(2), 155-163, doi: <https://link.springer.com/article/10.1007/s10928-019-09626-7>.
- Bhardwaj, P., Au, C.C., Martin, A.B., Ladumor, H., Oshchepkova, S., Moges, R. & Brown, K.A., 2019, Estrogens and Breast Cancer: Mechanisms Involved in Obesity-related Development, Growth and Progression,

Journal of Steroid Biochemistry and Molecular Biology, 189, 161-170, doi: <https://doi.org/10.1016/j.jsbmb.2019.03.002>.

Boster, B.L., Patel, N.K. & Michaud, L.B., 2020, *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh, McGrawHill, New York.

Cancer Registry, 2024, *RKBR Desember 2023*, <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-desember-2023/>, 14 Maret 2024.

Centers for Disease and Prevention, 2023, *What is Breast Cancer?*, https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm, 28 September 2023.

Deb, S. & Hopefl, R., 2022, Simulation of Drug-drug Interactions Between Breast Cancer Chemotherapeutic Agents and Antiemetic Drugs, *DARU Journal of Pharmaceutical Sciences*, doi: <https://doi.org/10.1007/s40199-023-00463-1>.

De-Cicco, P., Catani, M.V., Gasperi, V., Sibilano, M., Quaglietta, M. & Savini, I., 2019, Nutrition and Breast Cancer: A Literature Review on Prevention, Treatment, and Recurrence, *Nutrients*, 11(7), 1514, doi: <https://doi.org/10.3390/nu11071514>.

Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U. & Danesi, R., 2021, Drug-drug Interactions Between Palbociclib and Proton Pump Inhibitors may Significantly Affect Clinical Outcome of Metastatic Breast Cancer Patients, *ESMO Open*, 6(5), 100231, doi: <https://doi.org/10.1016/j.esmoop.2021.100231>.

Devarbhavi, H., Joseph, T., Kumar, N.S., Rathi, C., Thomas, V., Singh, P.S., Sawant, P., Goel, A., Eapen, C.E., Rai, P., Arora, A., Leelakrishnan, V., Gopalakrishnan, G., Reddy, V.V., Singh, R., Goswami, B., Venkataraman, J., Balaraju, G., Patil, M., Patel, R., Taneja, S., Koshy, A., Rao, N.P., Sarin K.S., Rathi, P., Dhiman, R., Duseja, A.K., Vargese, J., Jain, K.A., Wadhawan, M., Ranjan, P., Karanth, D., Ganesh, P., Nijhawan, S., Dhali, K.G., Adarsh, C.K., Jhaveri, A., Nagral, A., Rao, P., Shalimar, The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients, *Journal of Clinical and Experimental Hepatology*, 11(3), 288-298, doi: <https://doi.org/10.1016%2Fj.jceh.2020.11.002>.

Drugs.com, 2024, *Drug Interaction Checker*, URL: https://www.drugs.com/drug_interactions.html.

Ezhilarasan, D., 2021, Hepatotoxic Potentials of *Methotrexate*: Understanding the Possible Toxicological Molecular Mechanisms, *Toxicology*, 458, 152840, doi: <https://doi.org/10.1016/j.tox.2021.152840>.

Gounden, V., Bhatt, H. dan Jialal, I., 2023, Renal Function Tests, *National Library of Medicine*, URL: <https://www.ncbi.nlm.nih.gov/books/NBK507821/>.

- Hall, J.J., Bolina, M., Chatterley, T. & Jamali, F., 2016, Interaction Between Low-Dose *Methotrexate* and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors: A Narrative Review of the Literature, *Annals of Pharmacotherapy*, 51(2), doi: <https://doi.org/10.1177/1060028016672035>.
- Hanoodi, M. dan Mittal, M., 2023, *Methotrexate*, Start Pearls Publishing, National Library of Medicine, <https://www.ncbi.nlm.nih.gov/books/NBK556114/>.
- Hoemme, A., Barth, H., Haschke, M., Krahenbuhl, S., Strasser, F., Lehner, C., Von Kameke, A., Walti, T., Thurlimann, B., Fruh, M., Driessen, C. & Joerger M., 2019, Prognostic Impact of Polypharmacy and Drug Interactions in Patients with Advanced Cancer, *Cancer Chemotherapy and Pharmacology*, 83, 763-774, doi: <https://doi.org/10.1007/s00280-019-03783-9>.
- Howard, S.C., McCormick, J., Pui, C.H., Buddington, R.K. dan Harvey, R.D., 2016, Preventing and Managing Toxicities of High-Dose *Methotrexate*, *The Oncologist*, 21(12), 1471-1482, doi: <https://doi.org/10.1634/theoncologist.2015-0164>.
- Ishizaki, J., Nakano, C., Kitagawa, K., Suga, Y. Dan Sai, Y., 2020, A Previously Unknown Drug-drug Interaction is Suspected in Delayed Elimination of Plasma *Methotrexate* in High-Dose Therapy, *Ann Pharmacother*, 54(1), 29-35, doi: <https://doi.org/10.1177/1060028019870445>.
- Ismail, M., Khan, S., Khan, F., Noor, S., Sajid, H., Yar, S. & Rasheed I., 2020, Prevalence and Significance of Potential Drug-drug Interactions Among Cancer Patients Receiving Chemotherapy, *BMC Cancer*, 20, 335, doi: <https://doi.org/10.1186/s12885-020-06855-9>.
- Kaminska, M., Ciszewski, T., Lopacka-Szatan, K., Miotla, P. & Staroslawska, E., 2015, Breast Cancer Risk Factors, *Przegląd Menopauzalny*, 14(3), 196-202, doi: <https://doi.org/10.5114%2Fpm.2015.54346>.
- Kataoka, T., Sakurashita, H., Kajikawa, K., Saeki, Y., Taogoshi, T. dan Matsuo, H., 2021, Low Serum Albumin Level is a Risk Factor for Delayed *Methotrexate* Elimination in High-Dose *Methotrexate* Treatment, *Annals of Pharmacotherapy*, 55(10), 1195-1202, doi: <https://doi.org/10.1177/1060028021992767>.
- Kementerian Kesehatan RI, 2020, *Panduan Penatalaksanaan Kanker Payudara*, <https://www.kemkes.go.id/id/pnpk-2018---tata-laksana-kanker-payudara>.
- Kementerian Kesehatan RI, 2022, *Kanker Payudara Paling Banyak di Indonesia, Kemenkes Targetkan Pemerataan Layanan Kesehatan*, <https://sehatnegeriku.kemkes.go.id/baca/umum/20220202/1639254/kanker-payudaya-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan/>, 28 September 2023.
- Kolesar, J. dan Vermeulan, L., 2016, *Top 300 Pharmacy Drug Cards*, McGraw Hill Education.

- Leveque, D., Santucci, R., Gourieux, B. & Hebrecht, R., 2011, Pharmacokinetic Drug-drug Interactions with *Methotrexate* in Oncology, *Expert Rev Clin Pharmacol*, 4(7), 743-750, doi: <https://doi.org/10.1586/ecp.11.57>.
- Lien, K., Georgsdottir, S., Sivanathan, L., Chan, K. & Emmenegger, U., 2013, Low-dose Metronomic Chemotherapy: A Systematic Literature Analysis, *European Journal of Cancer*, 49(16), 3387-3395, doi: <https://doi.org/10.1016/j.ejca.2013.06.038>.
- Lovelace, D.L., McDaniel, L.R. & Golden, D., 2019, Long-Term Effects of Breast Cancer Surgery, Treatment, and Survivor Care, *Journal of Midwifery & Women's Health*, 64(6), 713-724, doi: <https://doi.org/10.1111/jmwh.13012>.
- Lucia, M., Luca, T., Federica, D.P., Cecilia, G., Chiara, M., Laura, D.M., Carlo, D.R. & Grazia, P.M., 2021, Opioids and Breast Cancer Recurrence: A Systematic Review, *Cancers*, 13(21), 5499, doi: <https://doi.org/10.3390/cancers13215499>.
- Lukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R. & Stanislawek, A., 2021, Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review, *Cancers (Basel)*, 13(17), 4287, doi: <https://doi.org/10.3390/cancers13174287>.
- Mariani, G., Petrelli, F., Zambetti, M., Moliterni, A., Fasolo, A., Marchiano, A., Valagussa, P. & Gianni, L., 2006, Capecitabine/Siklofosfamid/*Methotrexate* for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study, *Clinical Breast Cancer*, 7(4), 321-325, doi: <https://doi.org/10.3816/CBC.2006.n.044>.
- Masood, Shahla., 2016, Neoadjuvant Chemotherapy in Breast Cancers, *Women's Health*, 12(5), 480-491, doi: <https://doi.org/10.1177/1745505716677139>.
- Medscape, 2024, Drug Interaction Checker, URL: <https://reference.medscape.com/drug-interactionchecker>.
- Mitsuboshi, S., Niimura, T., Kanda, M., Ishida, S., Zamami, Y. & Ishizawa, K., 2021, Risk of Hematologic Events With Coadministration of *Methotrexate* and the Breast Cancer Resistance Protein Inhibitor Febuxostat, *Annals of Pharmacotherapy*, 56(8), 910-915, doi: <https://doi.org/10.1177/10600280211055794>.
- Momenimovahed, Z. & Salehiniya, H., 2019, Epidemiological Characteristics of and Risk Factors for Breast Cancer in the World, *Breast Cancer: Targets and Therapy*, 151-164, doi: <https://doi.org/10.2147/BCTT.S176070>.
- Moo, T.A., Sanford, R., Dang, C. & Morrow, M., 2018, Overview of Breast Cancer Therapy, *PubMed Central*, 13(3), 339-354, doi: <https://doi.org/10.1016/j.cpet.2018.02.006>.
- Muthana, F.M.S., Karuppannan, M., Abdulrahman, E., Uitrakul, S., Rasool, B.A.H. & Mohammed, A.H., Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A

- Prospective Study, *Advances in Pharmacological and Pharmaceutical Science*, 14, 7611733, doi: <https://doi.org/10.1155%2F2022%2F7611733>.
- Nami, B. & Wang, Z., 2018, Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance, *Cancers*, 10(8), 274, doi: <https://doi.org/10.3390/cancers10080274>.
- National Cancer Institute, 2021, *What is Cancer?*, <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>, 7 Oktober 2023.
- Nego, M.A. & Gayatri, A., 2023, Potential Drug Interactions in Critically Ill Patients, *Journal of The Indonesian Medical Association*, 73(4), 206-212, doi: <https://doi.org/10.47830/jinma-vol.73.4-2023-1036>.
- Rattay, B. dan Benndorf, R.A., 2021, Drug-Induced Idiosyncratic Agranulocytosis – Infrequent but Dangerous, *Front Pharmacol*, 12, 727717, doi: <https://doi.org/10.3389/fphar.2021.727717>.
- Shakeran, Z., Varshosaz, J., Keyhanfar, M., Beigi, H.M., Rahimi, K., Sutherland, D.S., 2022, Co-delivery of STAT3 siRNA and *Methotrexate* in Breast Cancer Cells, *Artificial Cells, Nanomedicine, and Biotechnology, An International Journal*, 50(1), 29-39, doi: <https://doi.org/10.1080/21691401.2022.2030746>.
- Shupp, A.B., Kolb, A.D., Mukhopadhyay, D. & Bussard, K.M., 2018, Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts, *Cancers*, 10(6), 182, doi: <https://doi.org/10.3390/cancers10060182>.
- Singh, H. dan Singh, B., 2017, Drug-drug Interactions in Cancer Chemotherapy: An Observational Study in a Tertiary Health Care Centre, *Drug Metabolism and Personalized Therapy*, 32(4), 219-223, doi: <https://doi.org/10.1515/dmpt-2017-0002>.
- Smorenburg, C.H., Sparreboom, A., Bontenbal, M. & Verweij, J., 2001, Combination Chemotherapy of the *Taxanes* and Antimetabolites: Its Use and Limitations, *European Journal of Cancer*, 37(18), 2310-2323, doi: [https://doi.org/10.1016/s0959-8049\(01\)00309-4](https://doi.org/10.1016/s0959-8049(01)00309-4).
- Solomon, D.H., Glynn, R.J., Karlson, E.W., Lu, F., Corrigan, C., Colls, J., Xu, C., MacFadyen, J., Barbhaiya, M., Berliner, N., Dellaripa, P.F., Everett, B.M., Pradhan, A.D., Hammond, S.P., Murray, M., Rao, D.A., Ritter, S., Rutherford, A., Sparks, J.A., Stratton, J., Suh, D.H., Tedeschi, S.K., Vanni, K.M.M., Paynter, N.P. & Ridker, P.M., 2020, Adverse Effects of Low-Dose *Methotrexate*: A Randomized Trial, *Ann Intern Med*, 172(6), 369-380, doi: <https://doi.org/10.7326%2FM19-3369>.
- Tatro, D.S., 2015, *Drug Interaction Fact 2015: The authority on drug interaction*, Wolters Kluwer Health/Facts & Comparisons, St. Louis, Missouri.
- Van den Boogaard, W.M.C., Komninos, D.S.J. & Vermeij, W.P., 2022, Chemotherapy Side-Effects: Not All DNA Damage is Equal, *Cancer (Basel)*, 14(3), 627, doi: <https://doi.org/10.3390%2Fcancers14030627>.

- Van Leeuwen, R.W.F., Brundel, D.H.S., Neef, C., Van Gelder, T., Mathijssen, R.H.J., Burger, D.M. & Jansman, F.G.A., 2013, Prevalence of Potential Drug-drug Interactions in Cancer Patients Treated with Oral Anticancer Drugs, *Br J Cancer*, 108(5), 1071-1078, doi: <https://doi.org/10.1038%2Fbjc.2013.48>.
- Wang, R., Zhu, Y., Liu, X., Liao, X., He, J. dan Niu, L., 2019, The Clinicopathological Features and Survival Outcomes of Patients with Different Metastatic Sites in Stage IV Breast Cancer, *BMC Cancer*, 19(1), doi: <https://doi.org/10.1186/s12885-019-6311-z>.
- Wells, B.G., Schwinghammer, T.L., Boster, J.T. & Boster, C.V., 2017, *Pharmacotherapy Handbook*, Tenth, McGrawHill, NewYork.
- Whittle, S.L. dan Hughes, R.A., 2004, Folate Supplementation and *Methotrexate* Treatment in Rheumatoid Arthritis: A Review, *Rheumatology*, 43(3), 267-271, doi: <https://doi.org/10.1093/rheumatology/keh088>.
- World Health Organization, 2022, *Cancer*, <https://www.who.int/news-room/fact-sheets/detail/cancer>, 7 Oktober 2023.
- World Health Organization, 2023, *Breast Cancer*, <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>, 28 September 2023.
- Wynn, G.H., Oesterheld, J.R., Cozza, K.L. & Armstrong, S.C., 2009, *Clinical Manual of Drug Interaction Principles for Medical Practice*, First, American Psychiatric Publishing, Inc., United States of America.
- Xu, D., Chen, X., Li, X., Mao, Z., Tang, W., Zhang, W., Ding, L. & Tang, J., 2019, Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients, *Journal of Cancer*, 10(2), 418-429, doi: <https://doi.org/10.7150%2Fjca.29739>.
- Yang, V., Gouveia, M.J., Santos, J., Koksche, B., Amorim, I., Gartner, F. & Vale, N., 2020, Breast Cancer: Insights in Disease and Influence of Drug *Methotrexate*, *The Royal Society of Chemistry*, doi: <https://doi.org/10.1039/D0MD00051E>.
- Yang, Y., Zhao, Z., Xie, C. & Zhao, Y., 2020, Dual-targeting Liposome Modified by Glutamic Hexapeptide and Folic Acid for Bone Metastatic Breast Cancer, *Chemistry and Physics of Lipids*, 228, 104882, doi: <https://doi.org/10.1016/j.chemphyslip.2020.104882>.